Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27369136 | 0.83 | KDM5B (0.37) | ALDH1A1MAPTCREBBP | |
| SCHEMBL21476010 | 0.80 | HRH3 (0.40) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| SCHEMBL24664733 | 0.73 | SORT1 (0.33) | ALDH1A1MEN1MAPTKMT2ACREBBP | |
| SCHEMBL22757227 | 0.72 | BRD4 (0.44) | HRH3LMNAALDH1A1CREBBP | |
| SCHEMBL3986304 | 0.70 | ALDH1A1 (0.38) | LMNAALDH1A1PLK1MEN1MAPT | |
| SCHEMBL1908661 | 0.69 | CPB2 (0.43) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| SCHEMBL1913121 | 0.65 | HRH3 (0.60) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| SCHEMBL30500455 | 0.63 | KDM5B (0.38) | HRH3ALDH1A1TDP1MAPTHRH4 | |
| SCHEMBL14384748 | 0.63 | HRH3 (0.43) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| SCHEMBL14385625 | 0.63 | CPB2 (0.56) | HRH3LMNAALDH1A1TAAR1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | HRH3 553/4885LMNA 2383/4885ALDH1A1 1361/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | HRH3 841/4885LMNA 2538/4885ALDH1A1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.